

Mary Philip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1195206/publications.pdf>

Version: 2024-02-01

23
papers

4,157
citations

623734

14
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

7038
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	22.7	345
2	Viral and cellular oncogenes promote immune evasion. <i>Oncogene</i> , 2022, 41, 921-929.	5.9	12
3	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	64
4	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. <i>Lancet Haematology</i> , 2021, 8, e562-e571.	4.6	28
5	CD226 Throttles up CD8+ T Cell Antitumor Activity. <i>Immunity</i> , 2020, 53, 704-706.	14.3	2
6	Alterations of T-cell-mediated immunity in acute myeloid leukemia. <i>Oncogene</i> , 2020, 39, 3611-3619.	5.9	52
7	Microenvironmental Metabolism Regulates Antitumor Immunity. <i>Cancer Research</i> , 2019, 79, 4003-4008.	0.9	91
8	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
9	Defining "T cell exhaustion"™. <i>Nature Reviews Immunology</i> , 2019, 19, 665-674.	22.7	879
10	Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. <i>Current Opinion in Immunology</i> , 2019, 58, 98-103.	5.5	83
11	Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. <i>British Journal of Haematology</i> , 2018, 183, 601-607.	2.5	7
12	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	27.8	643
13	TLR Stimulation Dynamically Regulates Heme and Iron Export Gene Expression in Macrophages. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	2.2	9
14	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , 2016, 45, 389-401.	14.3	496
15	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. <i>Blood</i> , 2016, 128, 1834-1834.	1.4	42
16	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. <i>Blood</i> , 2016, 128, 861-861.	1.4	0
17	Heme Exporter FLVCR Is Required for T Cell Development and Peripheral Survival. <i>Journal of Immunology</i> , 2015, 194, 1677-1685.	0.8	26
18	Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance. <i>Trends in Immunology</i> , 2015, 36, 665-667.	6.8	2

#	ARTICLE	IF	CITATIONS
19	FLVCR, a Heme Exporter, Is Required for Peripheral T Cell Survival.. Blood, 2012, 120, 2162-2162.	1.4	0
20	Full Dose Bendamustine (Treanda Â®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma. Blood, 2012, 120, 3650-3650.	1.4	0
21	Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4 ⁺ T cells. Immunology, 2010, 130, 494-503.	4.4	7
22	Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. Journal of Experimental Medicine, 2010, 207, 2469-2477.	8.5	116
23	Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology, 2004, 14, 433-439.	9.6	556